Bibliography
- PALINSKI W, TANGIRALA RK, MILLER E, YOUNG SG, WITZTUM JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1995) 15(10):1569-1576.
- AMELI S, HULTGARDH-NILSSON A, REGNSTROM J et al.: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. (1996) 16(8):1074-1079.
- FREIGANG S, HORKKO S, MILLER E, WITZTUM JL, PALINSKI W: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. (1998) 18(12):1972-1982.
- RITTERSHAUS CW, MILLER DP, THOMAS LJ et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2000) 20(9):2106-2112.
- NILSSON J, CALARA F, REGNSTROM J et al.: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. (1997) 30(7):1886-1891.
- BINDER CJ, HORKKO S, DEWAN A et al.: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. (2003) 9(6):736-743.
- FREDRIKSON GN, SODERBERG I, LINDHOLM M et al.: Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. (2003) 23(5):879-884.
- SCHIOPU A, BENGTSSON J, SODERBERG I et al.: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation (2004) 110(14):2047-2052.
- FREDRIKSON GN, HEDBLAD B, BERGLUND G et al.: Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. (2003) 23(5):872-878.
- WILLIAMS KJ, FEIG JE, FISHER EA: Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr. Opin. Lipidol. (2007) 18(4):443-450.
Patents
- KILPATRICK STOCKTON LLP: US20020018808 (2001).
- P DOINA INTERNATIONAL CO. LTD: US5424068 (1993).
- SMITHKLINE BEECHAM CORP.: US20030165503 (2002).
- GLAXOSMITHKLINE CORP.: US20040052809 (2003).
- GLAXOSMITHKLINE CORP.: US20040091496 (2003).
- AVANT IMMUNOTHERAPEUTICS, INC.: US6846808 (2001).
- REGENTS OF THE UNIVERSITY OF CALIFORNIA: US20070122419 (2004).
- HANSSON G, STEMME S, NICOLETTI A, WUTTGE D: US20040002111 (2002).
- BIOINVENT INTERNATIONAL AB: WO2007025781 (2006).
- FORSKARPATENT I SYD AB: WO02080954 (2002).
- FORSKARPATENT I SYD AB: WO2004030607 (2003).